Education
About Us
Working with TipRanks
Follow Us
ExpreS2ion Biotech Holding AB (DE:5JD0)
FRANKFURT:5JD0
Total Valuation
ExpreS2ion Biotech Holding AB has a market cap or net worth of €5.12M. The enterprise value is -€5.53M.
Market Cap€5.12M
Enterprise Value-€5.53M
Share Statistics
ExpreS2ion Biotech Holding AB has 3,530,233 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding3,530,233
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
ExpreS2ion Biotech Holding AB’s return on equity (ROE) is -1.07 and return on invested capital (ROIC) is -121.91%.
Return on Equity (ROE)-1.07
Return on Assets (ROA)-0.58
Return on Invested Capital (ROIC)-121.91%
Return on Capital Employed (ROCE)-1.43
Revenue Per Employee182.85K
Profits Per Employee-1.90M
Employee Count20
Asset Turnover0.06
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of ExpreS2ion Biotech Holding AB is ―. ExpreS2ion Biotech Holding AB’s PEG ratio is 0.03.
PE Ratio―
PS Ratio12.37
PB Ratio1.27
Price to Fair Value1.27
Price to FCF-1.11
Price to Operating Cash Flow-1.24
PEG Ratio0.03
Income Statement
In the last 12 months, ExpreS2ion Biotech Holding AB had revenue of 3.66M and earned -38.09M in profits. Earnings per share was -13.39.
Revenue3.66M
Gross Profit-42.84M
Operating Income-52.82M
Pretax Income-44.18M
Net Income-38.09M
EBITDA-51.35M
Earnings Per Share (EPS)-13.39
Cash Flow
In the last 12 months, operating cash flow was -40.90M and capital expenditures 0.00, giving a free cash flow of -40.90M billion.
Operating Cash Flow-40.90M
Free Cash Flow-40.90M
Free Cash Flow per Share-11.59
Dividends & Yields
ExpreS2ion Biotech Holding AB pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.77
52-Week Price Change-43.47%
50-Day Moving Average1.38
200-Day Moving Average1.71
Relative Strength Index (RSI)48.03
Average Volume (3m)0.00
Important Dates
ExpreS2ion Biotech Holding AB upcoming earnings date is May 19, 2026, TBA (Confirmed).
Last Earnings DateFeb 19, 2026
Next Earnings DateMay 19, 2026
Ex-Dividend Date―
Financial Position
ExpreS2ion Biotech Holding AB as a current ratio of 2.04, with Debt / Equity ratio of 6.18%
Current Ratio2.04
Quick Ratio2.04
Debt to Market Cap0.03
Net Debt to EBITDA0.88
Interest Coverage Ratio-117.12
Taxes
In the past 12 months, ExpreS2ion Biotech Holding AB has paid -6.09M in taxes.
Income Tax-6.09M
Effective Tax Rate0.14
Enterprise Valuation
ExpreS2ion Biotech Holding AB EV to EBITDA ratio is <0.01, with an EV/FCF ratio of <0.01.
EV to Sales-0.03
EV to EBITDA<0.01
EV to Free Cash Flow<0.01
EV to Operating Cash Flow<0.01
Balance Sheet
ExpreS2ion Biotech Holding AB has €47.55M in cash and marketable securities with €2.21M in debt, giving a net cash position of €45.35M billion.
Cash & Marketable Securities€47.55M
Total Debt€2.21M
Net Cash€45.35M
Net Cash Per Share€12.85
Tangible Book Value Per Share€12.54
Margins
Gross margin is -465.76%, with operating margin of -1444.35%, and net profit margin of -1041.43%.
Gross Margin-465.76%
Operating Margin-1444.35%
Pretax Margin-1208.07%
Net Profit Margin-1041.43%
EBITDA Margin-1404.24%
EBIT Margin-1444.35%
Analyst Forecast
The average price target for ExpreS2ion Biotech Holding AB is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―